Article

Dual 5-alpha-reductase inhibitor reduces BPH symptoms

Orlando, FL-A newer, novel 5-alpha-reductase inhibitor offersBPH symptom relief and improvements in urinary flow rates, according tofindings from three 2-year, multicenter, phase III trials.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Oral testosterone undecanoate shows promising results for first use in the real world
Oral testosterone undecanoate shows promising results for first use in the real world
Related Content
Pivotal data for lumasiran in PH1 published in NEJM
September 22nd 2025

Pivotal data for lumasiran in PH1 published in NEJM

Jason M. Broderick
Nedosiran explored in primary hyperoxaluria type 3
September 22nd 2025

Nedosiran explored in primary hyperoxaluria type 3

Jason M. Broderick
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
September 22nd 2025

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

Jason M. Broderick
Site Logo
September 22nd 2025

FDA approves androgen inhibitor for metastatic PCa

Site Logo
September 22nd 2025

Blood test could guide treatment for kidney cancer

Site Logo
September 22nd 2025

BCG for bladder cancer in short supply

© 2025 MJH Life Sciences

All rights reserved.